Our technology Solupore®

Current non-viral gene delivery technologies for cell therapy can negatively impact cell quality. This impact on cell health results in reduced proliferative capacity and cell function following the delivery of cargo, particularly in complex editing workflows. By enhancing cell quality, Solupore has the potential to improve in vitro and in vivo cell function, enabling the manufacture of next-generation gene-modified cell therapies.
‍

Application Notes

Automated reproducible transfection: A closed and robust non-viral delivery technology that enables complex editing workflows in cell therapy manufacturing.
Versatile delivery of cargo: Transfection of a broad range of cargo and gene-editing tools, including mRNA, CRISPR/Cas9, and plasmids to T cells and other blood cells.
Full GMP support by 1H 2025: GMP instrument and reagent supported by appropriate regulatory filings.

Commercialization

Partner access to Solupore technology under a range of agreements addressing applications in autologous cell therapy and non-viral stem cell reprogramming and editing.

Solupore® Benefits

Solupore technology has the potential to enhance patient access to autologous T cell therapies through healthier and more functional engineered cells. In IPS non-viral cell reprogramming of blood cells, Solupore technology is paving the way to reprogramming cells using RNA constructs, reducing development timelines, increasing flexibility and reducing regulatory hurdles.

Maintains optimal cell health & phenotype

Enhanced cell function after payload delivery

Ability to apply payload delivery for a wide range of applications

Capable of Integrating several manufacturing unit processes

Available as cGMP instrument by 1H 2025

How solupore® works

Solupore delivers cargo by physicochemical means, reversibly permeabilizing the cell membrane and yielding cells with superior health and a younger memory phenotype. Solupore® resolves key manufacturing limitations associated with viral and non-viral cell modification approaches.

Solupore®resolves key manufacturing limitations associated with viral and non-viral cell modification approaches

Manufacturing Challenges

Problem

Solution – Solupore®

Cell health & phenotype

Electroporation unintentionally activates and exhaust cells, negatively impacting cell viability

Younger memory phenotype and reduced apoptosis leading to improved proliferative capacity

Cell function

Poor cell function post editing negatively impacts clinical efficacy, safety, and tumor killing capability

Due to improved cell health and proliferative capacity, T cells are highly functional in vitro and in vivo

Complex gene-editing

Constraints around processing time, inflexibility and yield for sequential edits

Improved cell heath and function enable the complex editing needed for the next generation of cell therapies

Ease of adoption and use

Time consuming to scale up and cell processing requires highly skilled operators with batch-to-batch variability

Automated and closed system with minimal cell processing, flexible input parameters and ease of use

Cost of Goods

Multiple platforms and open steps

Cells processed within one closed device